Member Info for emptyend

The issue of the raise should be answered by one thing: Is the significant rise in revenue arriving in the form of cold, hard, cash……or not?

My impression has been that the squeeze on the company’s liquidity was at its greatest a year or so ago, when directors made loans.

Quite, Chelsea.

The context of my comment was a discussion involving various people who had held for 10-12 years. It is this year (not week) that monetisation is key. Since this may involve several unconnected events, it would be nice to see one of them quite soon……

Burble,

I don’t think your “light” is any different to mine. There is clearly value in collaborations etc. My issue is merely to see continual confirmation that Scancell, the company, is focused on its shareholders.

Lindy is a scientist - you can understand the focus and it has been her life’s work. But shareholders are here to make returns. They are interested to make returns, to see deals done, and to see timely progress made. Whilst there is no doubt that Vulpes and Redmile would share these priorities, there is a strong need to see that the Company’s management also shares a total focus on those issues, rather than on the science itself (even though they largely proceed in tandem).

The reason that the Scancell share price has languished is that the rate of progress, and the rate of execution of commercial deals, has disappointed shareholders.

The Company has existed now for a very long time and progress overall has been slow. Understandable whilst the Company was cash-strapped. But when Redmile turned up and offered to fully finance Scancell’s work programme, the Company had the opportunity to define its own work programme and objectives - and they took it, which is why there were two big rounds of funding done in 2020. But now the onus is on the Company to hit their own development milestones…..and we are getting into a very important six-month period where progress needs to be evidenced to shareholders by deals that have clear commercial value.

But so far we are still waiting - and seeing only fine words and backslapping events between scientists. It is time to “show us the money”!

Cleaner,

The three industrial partners are listed in the link you yourself provided: Iceni Glycoscience, Synthace Limited, Incepta Pharmaceuticals Ltd.

Lucknow is quite a good place for Cyan to be. The local authorities there want to develop it into the major commercial hub for the region - and it has quite a modern/western feel for an Indian city.

This is actually a piece I find a bit concerning as a shareholder. It renews lingering questions in my mind about whether shareholder value is front and centre in the company’s activities, or whether the company is just a bolt-on to a venture which is publicly-funded pure science, being pursued for its own sake.

Of couse there is a symbiosis here, but the company itself should be ENTIRELY focused on developing intellectual property and monetising it for the benefit of its shareholders.

I’d like to think we would get RNSs soon that prove that is the focus, and not the science alone…..

It was always obviously Goodfellow (or someone else no longer involves) and will clearly have been driven by tax-planning, to “take the taxable gain” at a time when the share price was low (and so the gain and tax on it will also be low). There will doubtless be another round very soon for 24/25.

Not impressed by an error in the published details - there is no excuse for sloppy errors re the exercise price!

Https://www.cancertherapyadvisor.com/reports/scib1-vaccine-nivo-ipi-melanoma/

….interesting read…..

The uncomfortable and very annoying fact, however, is that the share price is basically where is was in 2020, which is also roughly the same as Redmile’s average in-price and, more irritatingly, my own.

Other than the recent small fund raise since, I can see absolutely no reason why the share price is a mere fraction of “derisory” - other than the drag of being listed in London instead of the more vibrant and accurate NASDAQ.

The valuation gap needs to be closed as a matter of urgency……

The exit route here is a corporate deal, at some point in the next year or so, on the back of trial results and proof of platforms…..

The only things that matter here are data and deals. The rest is just noise.

But data and deals could literally happen at any time at all.

Meanwhile, Vulpes will be upgrading their adjectives from “derisory”…..

I notice BioNTech had something to say about pancreatic cancer, after their presentation….

https://www.investegate.co.uk/announcement/gnw/biontech-se-adr--0a3m/three-year-phase-1-follow-up-data-for-mrna-b-/8124400

The size of the room is irrelevant. The size of the audience’s corporate wallets is not……

I believe that is correct, Chelsea.

The fact that an abstract has been submitted does not preclude a presentation incorporating updates. Obviously, if that occurs, we should expect an RNS update at 7.00am tomorrow morning.

Brent $91 tonight.....might trigger some action?

Big close coming……..

Ray…..

…..Prime Time……🤔😉

Re the Q of moving the listing, it is clear that London hasn’t been the best place for capital-raising for at least the last ten years (which is when my own board drew that conclusion). Thank the regulatory over-reaction to the 2008 crisis and the chilling effect on risk-taking right across the City……and we now have a decade of underperformance of London-listed stocks that make matters even worse.

IMO there is simply no alternative, longer term, to listing abroad. The “Conservatives” have finally killed the London capital market that Mrs Thatcher’s era had supercharged.

Good time for option exercise IMO. Share price near a low so minimising the gain on exercise, whilst avoiding any tax hike from an incoming Labour government.

Clearly a fairly junior employee though from the quantum, so not an insider.

I think the “prime time” reference is clearly about priming the immune system to combat cancers. That is potentially quite interesting for platform technologies….